Examples
Worked examples
- Is an instance
A clinical-stage biotechnology company convenes a five- to seven-member SAB of academic and industry experts that meets quarterly to review unpublished pipeline data and advise the executive team on which indication to prioritize for the next trial — illustrative composite, not a specific real company.
- Is an instance
A university-affiliated research institute convenes an SAB to periodically review its overall research strategy and core-facility investment priorities, distinct from any single study's IRB or DSMB review.
Counter-examples
Looks similar, but isn't
- Not an instance
A committee with authority to review a specific trial's accumulating safety data and recommend continuing, modifying, or stopping that trial is a DSMB, not a Scientific Advisory Board — an SAB has no such data-monitoring authority.
- Not an instance
A committee formally charged with approving or disapproving a human-subjects research protocol before enrollment can begin is an IRB, not a Scientific Advisory Board, regardless of internal naming.
Editorial commentary
A Scientific Advisory Board (SAB) is a standing panel of external, independent subject-matter experts convened by a company, research institution, foundation, or funded program to advise its leadership on scientific direction, strategy, and priorities — for example, which research programs or pipeline assets to advance, what emerging science is relevant to the organization’s mission, and how its scientific approach compares with the wider field. An SAB is an advisory body, not a governing or regulatory one: it has no independent authority to approve, halt, or modify a specific study, and its recommendations are non-binding on the organization’s actual decision-makers (a company’s board of directors and executive team, or an institution’s leadership).
What a Scientific Advisory Board actually does
An SAB’s remit is strategic and scientific rather than operational or regulatory. Typical activities include reviewing research and development plans, critiquing preliminary or unpublished data, advising on which indications, technologies, or research questions to prioritize, helping recruit scientific talent or collaborators, and lending scientific credibility when the organization engages investors, funders, or partners. Members are usually academic researchers, clinicians, former regulators, or industry veterans chosen for expertise the organization’s own staff doesn’t fully have in-house. SABs typically meet periodically — quarterly or semi-annually is common for company boards — rather than continuously, and members are usually compensated through some combination of a cash retainer or per-meeting fee and, for company SABs, equity or stock options; the exact structure varies widely and isn’t standardized.
Because an SAB is advisory rather than fiduciary, its members typically carry none of the legal duties (e.g. duty of care, duty of loyalty) that attach to a formal board of directors, and none of the regulatory authority that attaches to an Institutional Review Board (IRB) or a Data and Safety Monitoring Board (DSMB). This is the single most important distinction to keep straight: an SAB’s value is the quality of its advice, not any formal power to compel a decision.
Typical composition
Composition is deliberately matched to the organization’s scientific gaps rather than following a fixed template, but recurring patterns include:
- A chair — often a senior, widely recognized figure in the relevant field, sometimes a former regulator or distinguished academic, who helps set the board’s agenda and credibility.
- Therapeutic-area or domain experts — academic or clinical specialists in the specific disease areas, technology platforms, or research questions the organization works on.
- Clinical development or regulatory advisors — particularly common on biotech/pharma company SABs, where members with trial-design or prior agency experience advise on development pathways.
- Commercial or translational advisors — on company SABs, members who understand how research findings move toward a marketable product or clinical application.
SAB membership, and any resulting compensation or equity, is a type of external relationship that falls squarely within standard conflict-of-interest disclosure practice — see conflict of interest disclosure — particularly when an academic member also serves as an investigator on research the same company sponsors.
Where Scientific Advisory Boards appear
The label “SAB” spans several distinct contexts that share the same basic function (external expert advice on scientific strategy) but differ in scope:
- Biotech/pharma company SAB — the most visible context. A clinical-stage or research-stage company convenes an SAB to advise its executive team and board of directors on pipeline strategy, emerging science relevant to its platform, and which programs to prioritize for the next round of development. Publicly traded companies commonly disclose SAB membership in investor-facing materials as a signal of scientific credibility to the market.
- Large research center or institute SAB — a university-affiliated research center, national laboratory, or large multi-investigator institute convenes an SAB (sometimes called a Scientific Advisory Committee) to periodically review the center’s overall research direction, core facility investments, and strategic priorities, typically as part of a broader institutional or funder-mandated review cycle rather than reviewing individual protocols.
- Foundation or funder SAB — a research foundation or funding program convenes an SAB to advise on funding strategy and priority areas — which scientific questions or fields the foundation’s resources should target — as distinct from the peer-review study sections that actually score individual grant applications.
SAB vs. Data and Safety Monitoring Board (DSMB): strategic advice vs. ongoing trial-safety oversight
An SAB and a Data and Safety Monitoring Board (DSMB, also called a Data Monitoring Committee, DMC) are easy to conflate because both sit outside the day-to-day study or company team and both involve outside scientific expertise — but they answer fundamentally different questions and operate under different authority:
- SAB: advises on scientific strategy and direction — which programs or questions to pursue, how the organization’s science compares with the field — on an ongoing but periodic basis. It does not review a specific trial’s accumulating safety or efficacy data, and it has no authority to change a protocol or stop a study.
- DSMB/DMC: an independent body, external to the study team, that periodically reviews a specific trial’s accumulating data — adverse events, efficacy endpoints, data completeness — once the trial is enrolling, and can recommend continuing, modifying, or stopping that trial on safety or futility grounds. The U.S. Food and Drug Administration’s guidance on data monitoring committees (originally issued in 2006 as “Establishment and Operation of Clinical Trial Data Monitoring Committees,” with a 2024 draft revision, “Use of Data Monitoring Committees in Clinical Trials,” in progress) recommends a DMC particularly where safety concerns are unusually high — for example, vulnerable populations or high morbidity/mortality studies. NIH’s 1998 Policy for Data and Safety Monitoring similarly treats DSMB oversight as a requirement distinct from, and additional to, IRB review for higher-risk multi-site trials.
In short: an SAB asks “is this the right science to be pursuing, and is our overall approach sound?” A DSMB asks, only once a specific trial is actually enrolling, “does the accumulating data mean this trial should continue, change, or stop?” An organization can have both simultaneously — a company SAB advising on which programs to fund, and a separate DSMB monitoring one of that company’s Phase III trials — serving entirely different functions for entirely different audiences. See also Scientific Review Committee (SRC), an institutional body distinct from both an SAB and a DSMB: an SRC evaluates a specific protocol’s scientific merit and feasibility before it opens, most commonly at NCI-designated cancer centers, rather than advising on organization-wide strategy (the SAB’s role) or monitoring accumulating trial data (the DSMB’s role).
SAB vs. Institutional Review Board (IRB): strategic advice vs. ethics review
An SAB is also not a substitute for, or a version of, an Institutional Review Board (IRB). An IRB is a formally constituted committee, required under the Common Rule (45 CFR 46) for federally funded human-subjects research and under 21 CFR Part 56 for FDA-regulated studies, whose jurisdiction is human-subjects protection: informed consent, risk-benefit balance for participants, privacy safeguards, and equitable subject selection. An IRB must review and approve a specific human-subjects research protocol before it can begin, and it has statutory authority to require modifications or disapprove a study outright. An SAB has neither that jurisdiction nor that authority — it does not review individual protocols for ethical compliance, and its advice on scientific strategy is never a substitute for required IRB approval. A company or institution can convene an SAB without that having any bearing on whether its human-subjects research still needs, and has, IRB approval.
Illustrative example (composite, not a specific organization)
A clinical-stage biotechnology company might convene a five-member SAB — a chair with deep expertise in the company’s core therapeutic area, two academic specialists in adjacent disease areas, a former regulatory official, and a clinical-development veteran — that meets quarterly to review unpublished preclinical and early clinical data and advise the executive team on which of two candidate indications to prioritize for the company’s next trial. The board has no authority to approve the trial itself; that determination still requires the company’s own governance decision, IRB approval for the human-subjects protocol, and, separately, a DSMB once the trial is enrolling if the study’s risk profile warrants one. This composite illustrates the pattern; it is not a description of any specific real company or board.
Counter-example
A committee with the authority to recommend continuing, modifying, or stopping a specific ongoing trial based on accumulating interim safety or efficacy data is not a Scientific Advisory Board — that defined, data-driven safety function is a DSMB’s role, not an SAB’s. Likewise, a committee whose formal charge is to approve or disapprove a human-subjects research protocol before it can begin is an IRB, not an SAB, regardless of what an organization happens to call it internally.
References
- FDA, “Establishment and Operation of Clinical Trial Data Monitoring Committees” (Guidance for Clinical Trial Sponsors, March 2006); draft revision “Use of Data Monitoring Committees in Clinical Trials” (2024) — fda.gov.
- NIH, “NIH Policy for Data and Safety Monitoring,” NOT-98-084 (June 10, 1998), grants.nih.gov — establishes DSMB requirements for higher-risk multi-site trials, distinct from IRB review.
- 45 CFR 46 (the Common Rule), Subpart A; 21 CFR Part 56 — define IRB jurisdiction over human-subjects research ethics review.
Machine-readable encodings
Use in your systems
<role vocab="credit"
vocab-identifier="https://casrai.org/dictionary/"
vocab-term="Scientific Advisory Board (SAB)"
vocab-term-identifier="https://casrai.org/dictionary/term/scientific-advisory-board" />{
"@context": "https://schema.org",
"@type": "DefinedTerm",
"@id": "https://casrai.org/dictionary/term/scientific-advisory-board",
"name": "Scientific Advisory Board (SAB)",
"identifier": "https://casrai.org/dictionary/term/scientific-advisory-board",
"description": "An external, independent panel of subject-matter experts convened by a company, research institution, foundation, or funded program to advise leadership on scientific direction and strategy — which programs, indications, or research questions to prioritize, and how the organization's science compares with the field. An SAB is advisory only: it has no governing, regulatory, or fiduciary authority, no independent power to approve, halt, or modify a specific study or protocol, and its recommendations are non-binding.",
"inDefinedTermSet": "https://casrai.org/dictionary/domain/compliance-regulatory#set",
"url": "https://casrai.org/dictionary/term/scientific-advisory-board",
"sameAs": [],
"license": "https://creativecommons.org/licenses/by/4.0/",
"publisher": {
"@id": "https://casrai.org/#organization"
},
"dateModified": "2026-07-17T02:44:15",
"inLanguage": "en"
}
